




Supplementary Figure 1. Model performance for **(A)** 3-year and **(B)** 5-year atherosclerosis risk prediction using the AUROC (left) and the AUPRC (right).



Supplementary Figure 2. Consistent model performance across ethnicities. (A) The performances of the EBM Proteomics & Clinical, and the EBM Proteomics models are consistent across self-reported ethnicities. **(B)** Overall, the EBM Proteomics & Clinical model outperforms other traditional models across ethnicities. Only ethnicities with at least five cases are reported. Error bars show the 95% confidence interval.




Supplementary Figure 3. Model performance across various subpopulations. The mean value is represented with a dot, and the 95% confidence interval with the error bars. The dashed line represents the mean AUROC across the entire cohort, and the gray shaded area shows its 95% confidence interval.




Supplementary Figure 4. Model performance in predicting three CVD outcomes within 10 years: ischemic stroke (ISS), coronary artery disease (CAD), and myocardial infarction (MI). The performance is represented by the AUROC on the left side and the AUPRC on the right side.

3-year		5-year	10-year
HAVCR1		MMP12	HAVCR1
CHCHD10_II		HAVCR1	MMP12
MMP12		NT-proBNP	NT-proBNP
GDF15	//	NPPB	NPPB
HK2	1	KLK4	PLA2G7
KLK4	/ /X	CEACAM5	CHRDL2
CCL11	/// `	GDF15	FASLG
NT-proBNP	Y /	EDA2R	GDF15
PRSS8		TNNI3	CDCP1
NPPB	Y	CDCP1	LTBP2


Supplementary Figure 5. Top 10 contributing proteins at different time horizons. The shared features are connected by orange lines. Notably, six of the top 10 features were shared between the 3-and 5-year predictions, as well as between the 5-year and 10-year predictions. Biomarkers that have been previously identified are highlighted with a green shade.




Supplementary Figure 6. SHAP values of the top 50 features in the LightGBM models. The seven features that overlap with the top 10 features in the EBM Proteomics & Clinical model are highlighted in red. 6153_-7: none of the above for "Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones". 21003: Age when attended assessment centre. 6150_-7: none of the above for "Vascular/heart problems diagnosed by doctor". 21022: Age at recruitment.




Supplementary Figure 7. (A) NT-proBNP and **(B)** NPPB, both involved in the natriuretic peptide system, show similar disease risk profile. Note the scale of the Y-axis on the panels were different, and NT-proBNP has a more profound impact than NPPB. The top panels of each subfigure display the risk score on the logarithmic scale for different feature values, with gray shaded regions representing the standard deviation for estimations. The bottom panels show histograms of the feature values across all participants.




Supplementary Figure 8. Risk profile of NT-ProBNP in the EBM Proteomics & Clinical model. It shows a weaker impact compared to that of the EBM Proteomics model (Supplementary Figure 7A). The top panel displays the risk score on the logarithmic scale for different feature values, with gray shaded regions representing the standard deviation for estimations. The bottom panel shows histograms of the feature values across all participants.







Supplementary Figure 9. Risk profiles of **(A)** HDL and **(B)** PCSK9 in the EBM Proteomics & Clinical model. The top panels of each subfigure display the risk score on the logarithmic scale for different feature values, with gray shaded regions representing the standard deviation for estimations. The bottom panels show histograms of the feature values across all participants.



Supplementary Figure 10. The list of top 10 features is shown for **(A)** models built based on random split, **(B)** separate models built for different genders, **(C)** ages, and **(D)** BMIs, respectively, in the EBM Proteomics & Clinical model. We split age and BMI based on the median value. Shared features between splits were highlighted in green and linked by orange lines. Random splits share 7/10 features, while split by gender, age and BMI have 3, 2 and 5 shared top 10 features respectively. The feature encodings of the clinical features are listed in Table S3.



Supplementary Figure 11. The feature importance for Top 100 features were plotted against models based on the two data splits. Pearson's R and the associated P values are shown in the upper right corner. Shared top 10 features in both data splits are highlighted in red. Note that the clinical fields 21022 (Age at recruitment) and 21003 (Age when attended assessment center) were highly correlated, shown as overlapping dots with similar feature importance. The other displayed clinical fields were 54 (UK Biobank assessment center) and 6153_-7 (None of the above for "Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones").



Supplementary Figure 12. Phenotypic characteristics of the participants in the different data splits were consistent.

Table S1. Comparison of discrimination and reclassification performance between various EBM models and QRISK3 over a 10-year time horizon.

		A. QRISK3 vs. EBM Clinical	B. QRISK3 vs EBM Proteomics	C. QRISK3 vs EBM Proteomics & Clinical	D. EBM Proteomics vs EBM Proteomics & Clinical
	Index	0.5908	0.5538	0.708	0.3657
NRI	95% CI	(0.3566, 0.825)	(0.3157, 0.7918)	(0.4763, 0.9397)	(0.1445, 0.587)
	P-value	.0001 ***	.0001 ***	< .0001 ****	.0033 **
IDI	Index	0.0635	0.0555	0.0926	0.0329
	95% CI	(0.0213, 0.1057)	(0.0235, 0.0874)	(0.0474, 0.1379)	(0.0044, 0.0615)
	P-value	.0134 *	.0047 **	.0004 ***	.0463 *

P-value: *: P<.05; **: P<.01; ***: P<.001; ****: P<.0001

Table S2. Clinical features among the top 20 most important features in the EBM Proteomics & Clinical model. Note that no directionality is implied regarding how the predictive value influences CVD risk.

Rank	Variable (field number)	Predictive value(s) (when multiple values are allowed)
2	Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones (6153)	None of the above
3	Assessment center (54)	-
6	Illnesses of father (20107)	Heart disease
8	Illnesses of mother (20110)	Heart disease
9	Age when attended assessment center (21003)	-
10	Age at recruitment (21022)	-
11	Qualifications (6138)	College or University degree
13, 14	Vascular/heart problems diagnosed by doctor (6150)	High blood pressure, None of the above
15	Systolic blood pressure, automated reading (4080)	-
16	Glycated hemoglobin (HbA1c) (30750)	-
17	Medication for cholesterol, blood pressure or diabetes (6177)	Missing value
18	Sex (31)	-
19	LDL levels (30780)	-

Table S3. Disease codes used to define atherosclerosis events.

Phenotype	ICD-9	ICD-10	OPCS-4	Self-reported
Coronary artery disease	410, 411, 412	I20, I21, I22, I23, I24, I25	K40, K41, K42, K43, K44, K45, K46, K49, K501, K759	1075
Ischemic stroke	434, 436	163, 164	-	1583
Myocardial infarction	410, 411, 412	I21, I22, I23, I24, I252	-	1075

Table S4. Count of cases at different time horizons for the entire cohort, and separately for men and women. The total number of participants is shown in parenthesis within the studied cohort.

Time horizon	Total	Men	Women
3-year outcome	789 (49,650)	506 (22,035)	283 (27,615)
5-year outcome	1,460 (49,254)	922 (21,824)	538 (27,430)
10-year outcome	3,287 (46,009)	1,999 (20,269)	1,288 (25,740)

Table S5. Different clinical features exhibit various degrees of data missingness.

(Shared separately)

Table S6. Mean performance and 95% confidence interval of the models shown in Supplementary Figure 4. The best performing model in each column for each outcome is highlighted in bold.

Table S6.1. Area under the receiver operating characteristic curve

Clinical outcome	Data	Model	Overall	Women	Men
Coronary artery disease	Proteomics & Clinical	EBM	0.7846 ± 0.0055	0.7699 ± 0.0127	0.7673 ± 0.0078
Coronary artery disease	Proteomics & Clinical	LightGBM	0.7761 ± 0.0090	0.7612 ± 0.0133	0.7587 ± 0.0102
Coronary artery disease	Proteomics	EBM	0.7660 ± 0.0078	0.7468 ± 0.0137	0.7498 ± 0.0073
Coronary artery disease	Clinical	EBM	0.7703 ± 0.0041	0.7595 ± 0.0123	0.7457 ± 0.0100
Coronary artery disease	Clinical	QRISK3	0.7244 ± 0.0102	0.7074 ± 0.0114	0.6987 ± 0.0120
Coronary artery disease	Clinical	PCE	0.6935 ± 0.0080	0.7180 ± 0.0096	0.6997 ± 0.0112
Coronary artery disease	Clinical	SCORE2	0.6919 ± 0.0078	0.7025 ± 0.0114	0.6935 ± 0.0118
Coronary artery disease	Genetics	CVD PRS	0.5782 ± 0.0116	0.5732 ± 0.0102	0.5860 ± 0.0151
Coronary artery disease	Genetics	CAD PRS	0.5829 ± 0.0074	0.5774 ± 0.0118	0.5907 ± 0.0082
Coronary artery disease	Genetics	ISS PRS	0.5497 ± 0.0116	0.5580 ± 0.0131	0.5482 ± 0.0143
Coronary artery disease	Genetics	HT PRS	0.5459 ± 0.0090	0.5552 ± 0.0223	0.5418 ± 0.0104
Ischemic stroke	Proteomics & Clinical	EBM	0.8020 ± 0.0200	0.7981 ± 0.0325	0.7937 ± 0.0269
Ischemic stroke	Proteomics & Clinical	LightGBM	0.7922 ± 0.0178	0.7831 ± 0.0325	0.7877 ± 0.0249
Ischemic stroke	Proteomics	EBM	0.7890 ± 0.0176	0.7807 ± 0.0312	0.7838 ± 0.0263
Ischemic stroke	Clinical	EBM	0.7778 ± 0.0169	0.7758 ± 0.0284	0.7640 ± 0.0227
Ischemic stroke	Clinical	QRISK3	0.7255 ± 0.0155	0.7310 ± 0.0384	0.7257 ± 0.0206
Ischemic stroke	Clinical	PCE	0.6859 ± 0.0171	0.7341 ± 0.0368	0.7225 ± 0.0208
Ischemic stroke	Clinical	SCORE2	0.7298 ± 0.0165	0.7193 ± 0.0427	0.7360 ± 0.0186
Ischemic stroke	Genetics	CVD PRS	0.5629 ± 0.0306	0.5445 ± 0.0445	0.5788 ± 0.0380
Ischemic stroke	Genetics	CAD PRS	0.5294 ± 0.0294	0.5329 ± 0.0459	0.5290 ± 0.0414
Ischemic stroke	Genetics	ISS PRS	0.5883 ± 0.0192	0.5845 ± 0.0296	0.5931 ± 0.0286
Ischemic stroke	Genetics	HT PRS	0.5655 ± 0.0231	0.5734 ± 0.0400	0.5608 ± 0.0308
Myocardial infarction	Proteomics & Clinical	EBM	0.7937 ± 0.0108	0.7874 ± 0.0214	0.7667 ± 0.0114
Myocardial infarction	Proteomics & Clinical	LightGBM	0.7834 ± 0.0147	0.7768 ± 0.0267	0.7551 ± 0.0153
Myocardial infarction	Proteomics	EBM	0.7739 ± 0.0141	0.7605 ± 0.0263	0.7486 ± 0.0120
Myocardial infarction	Clinical	EBM	0.7792 ± 0.0098	0.7779 ± 0.0174	0.7442 ± 0.0147
Myocardial infarction	Clinical	QRISK3	0.7358 ± 0.0096	0.7232 ± 0.0180	0.6942 ± 0.0172
Myocardial infarction	Clinical	PCE	0.7071 ± 0.0096	0.7405 ± 0.0172	0.6837 ± 0.0184
Myocardial infarction	Clinical	SCORE2	0.6934 ± 0.0172	0.7295 ± 0.0163	0.6831 ± 0.0212
Myocardial infarction	Genetics	CVD PRS	0.6008 ± 0.0186	0.5882 ± 0.0284	0.614 ± 0.0202
Myocardial infarction	Genetics	CAD PRS	0.6155 ± 0.0225	0.6042 ± 0.0302	0.6273 ± 0.0263
Myocardial infarction	Genetics	ISS PRS	0.5577 ± 0.0098	0.5531 ± 0.0298	0.5648 ± 0.0100
Myocardial infarction	Genetics	HT PRS	0.5525 ± 0.0165	0.5521 ± 0.0265	0.5558 ± 0.0216

Table S6.2. Area under the precision-recall curve

Clinical outcome	Data	Model	Overall	Women	Men
Coronary artery disease	Proteomics & Clinical	EBM	0.2591 ± 0.0125	0.1943 ± 0.0172	0.296 ± 0.0194
Coronary artery disease	Proteomics & Clinical	LightGBM	0.2176 ± 0.0125	0.1613 ± 0.0145	0.2519 ± 0.0186
Coronary artery disease	Proteomics	EBM	0.2157 ± 0.0165	0.1454 ± 0.0155	0.2581 ± 0.0214
Coronary artery disease	Clinical	EBM	0.2364 ± 0.0078	0.1872 ± 0.0167	0.2633 ± 0.0153
Coronary artery disease	Clinical	QRISK3	0.1463 ± 0.0090	0.1048 ± 0.0086	0.171 ± 0.0135
Coronary artery disease	Clinical	PCE	0.1413 ± 0.0074	0.1052 ± 0.0092	0.1754 ± 0.0112
Coronary artery disease	Clinical	SCORE2	0.1256 ± 0.0069	0.0987 ± 0.0092	0.162 ± 0.0071
Coronary artery disease	Genetics	CVD PRS	0.0833 ± 0.0033	0.0575 ± 0.0051	0.1213 ± 0.0078
Coronary artery disease	Genetics	CAD PRS	0.0845 ± 0.0031	0.0583 ± 0.0029	0.1218 ± 0.0059
Coronary artery disease	Genetics	ISS PRS	0.0747 ± 0.0039	0.0528 ± 0.0033	0.1064 ± 0.0080
Coronary artery disease	Genetics	HT PRS	0.0746 ± 0.0027	0.0541 ± 0.0041	0.1041 ± 0.0053
Ischemic stroke	Proteomics & Clinical	EBM	0.0991 ± 0.0202	0.0868 ± 0.0298	0.1105 ± 0.0308
Ischemic stroke	Proteomics & Clinical	LightGBM	0.0735 ± 0.0141	0.0587 ± 0.0176	0.0926 ± 0.0214
Ischemic stroke	Proteomics	EBM	0.0708 ± 0.0123	0.0578 ± 0.0153	0.0927 ± 0.0243
Ischemic stroke	Clinical	EBM	0.0948 ± 0.0245	0.0913 ± 0.0325	0.1029 ± 0.0272
Ischemic stroke	Clinical	QRISK3	0.0416 ± 0.0073	0.0392 ± 0.0143	0.0529 ± 0.0106
Ischemic stroke	Clinical	PCE	0.0472 ± 0.0143	0.039 ± 0.0131	0.0664 ± 0.0194
Ischemic stroke	Clinical	SCORE2	0.052 ± 0.0110	0.0346 ± 0.0116	0.0677 ± 0.0184
Ischemic stroke	Genetics	CVD PRS	0.0183 ± 0.0031	0.0179 ± 0.0088	0.0251 ± 0.0043
Ischemic stroke	Genetics	CAD PRS	0.0158 ± 0.0024	0.0127 ± 0.0025	0.022 ± 0.0041
Ischemic stroke	Genetics	ISS PRS	0.0205 ± 0.0027	0.0175 ± 0.0047	0.0279 ± 0.0035
Ischemic stroke	Genetics	HT PRS	0.0176 ± 0.0014	0.014 ± 0.0025	0.0241 ± 0.0029
Myocardial infarction	Proteomics & Clinical	EBM	0.1472 ± 0.0106	0.113 ± 0.0202	0.1643 ± 0.0129
Myocardial infarction	Proteomics & Clinical	LightGBM	0.1117 ± 0.0104	0.0899 ± 0.0167	0.1297 ± 0.0159
Myocardial infarction	Proteomics	EBM	0.112 ± 0.0139	0.0749 ± 0.0176	0.1405 ± 0.0220
Myocardial infarction	Clinical	EBM	0.1385 ± 0.0131	0.1184 ± 0.0143	0.1503 ± 0.0178
Myocardial infarction	Clinical	QRISK3	0.0705 ± 0.0088	0.0406 ± 0.0051	0.0845 ± 0.0135
Myocardial infarction	Clinical	PCE	0.0688 ± 0.0102	0.0547 ± 0.0186	0.0866 ± 0.0159
Myocardial infarction	Clinical	SCORE2	0.0608 ± 0.0108	0.0543 ± 0.0176	0.0776 ± 0.0104
Myocardial infarction	Genetics	CVD PRS	0.0393 ± 0.0037	0.0287 ± 0.0086	0.06 ± 0.0074
Myocardial infarction	Genetics	CAD PRS	0.0401 ± 0.0035	0.0259 ± 0.0031	0.0626 ± 0.0073
Myocardial infarction	Genetics	ISS PRS	0.0339 ± 0.0041	0.0231 ± 0.0061	0.0549 ± 0.0106
Myocardial infarction	Genetics	HT PRS	0.0323 ± 0.0033	0.0215 ± 0.0065	0.051 ± 0.0057